Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 3/20 | 0.57 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.57 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.46 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22191227 | 0.90 | PDE3B (0.47) | PDE3BPDE3AGRIA1CACNG8KDM4E | |
| SCHEMBL22191410 | 0.88 | MAPT (0.50) | PDE3BPDE3AGRIA1CACNG8DYRK1A | |
| SCHEMBL22191660 | 0.88 | THRB (0.50) | PDE3BPDE3AGRIA1CACNG8DYRK1A | |
| SCHEMBL22191691 | 0.88 | PLK4 (0.48) | PDE3BPDE3AGRIA1CACNG8KDM4E | |
| SCHEMBL22191151 | 0.87 | BCL6 (0.48) | PDE3BPDE3AGRIA1CACNG8DYRK1A | |
| SCHEMBL22191749 | 0.85 | LRRK2 (0.47) | PDE3BPDE3AGRIA1CACNG8DYRK1A | |
| SCHEMBL22191159 | 0.85 | KDM4E (0.47) | PDE3BPDE3ADYRK1AKDM4EFYN | |
| SCHEMBL22191669 | 0.84 | DYRK1A (0.46) | PDE3BPDE3AGRIA1CACNG8DYRK1A | |
| SCHEMBL22191426 | 0.82 | GABRA1 (0.43) | PDE3BPDE3AGRIA1CACNG8KDM4E | |
| SCHEMBL22191347 | 0.82 | PDE3B (0.60) | PDE3BPDE3AGRIA1CACNG8DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3906233-B1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL MED MOUNT SINAI (US) | 2024-01-31 | — | — | EP | disclosed |
| US-20220162182-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-05-26 | — | — | US | disclosed |
| US-20220162182-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-05-26 | — | — | US | disclosed |
| EP-3906233-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | Icahn School of Medicine at Mount Sinai (US) | 2021-11-10 | — | — | EP | disclosed |
| CN-113508111-A | Kinase inhibitor compounds and compositions and methods of use | 西奈山伊坎医学院 | 2021-10-15 | — | — | CN | disclosed |
| WO-2020142485-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2020-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162182-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | MAP3K20, MAP3K1, PACSIN2 | PDE3B 855/4885PDE3A 729/4885GRIA1 1007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.